Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe

This publication has 30 references indexed in Scilit:

• Serotonin 2A receptor antagonists for treatment of schizophrenia
  Expert Opinion on Investigational Drugs, 2011
• Training for Assessment of Negative Symptoms of Schizophrenia across Languages and Cultures: Comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom Factor
  Clinical Schizophrenia & Related Psychoses, 2011
• Methodological Issues in Negative Symptom Trials
  Schizophrenia Bulletin, 2011
• Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice
  The Journal of Clinical Psychiatry, 2009
• PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain
  International Journal of Neuropsychopharmacology, 2007
• Persistent Negative Symptoms in Schizophrenia: An Overview
  Schizophrenia Bulletin, 2007
• Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers
  American Journal of Psychiatry, 2006
• N-Desmethylclozapine, a Major Metabolite of Clozapine, Increases Cortical Acetylcholine and Dopamine Release In Vivo Via Stimulation of M1 Muscarinic Receptors
  Neuropsychopharmacology, 2005
• Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder
  American Journal of Psychiatry, 2004
• Validation of the 16-item negative symptom assessment
  Journal of Psychiatric Research, 1993